Volume 24 Number 20
31 October 2022

Home > Publications > Neuro-Oncology Reviews > Volume 24, Year 2022 > Number 20, 31 October

Zhang J, Siller-Farfán JA.
Current and future perspectives of chimeric antigen receptors against glioblastoma.
Immunother Adv. 2022 Jun 1, 2022;2(1):ltac014. doi: 10.1093/immadv/ltac014. PMID: 36284838. Review.

Khalil M, Shah Z, Saeed Baqai MW, Shamim MS.
Intraoperative Seizures During Awake Craniotomy for Brain Tumours.
J Pak Med Assoc. 2022 Sep;72(9):1878-1879. doi: 10.47391/JPMA.22-95? PMID: 36281000. Review.

Li Y, Qin Q, Zhang Y, Cao Y.
Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis.
Curr Oncol. 2022 Sep 23, 2022;29(10):6893-6907. doi: 10.3390/curroncol29100542. PMID: 36290819. Review.

Lim-Fat MJ, Macdonald M, Lapointe S, Climans SA, Cacciotti C, Chahal M, Perreault S, Tsang DS, Gao A, Yip S, Keith J, Bennett J, Ramaswamy V, Detsky J, Tabori U, Das S, Hawkins C.
Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline.
Front Oncol. 2022 Sep 23, 2022;12:960509. doi: 10.3389/fonc.2022.960509. PMID: 36249063. Guidelines.

Rossi J, Cavallieri F, Biagini G, Rizzi R, Russo M, Cozzi S, Giaccherini L, Pisanello A, Valzania F.
Epileptogenesis and Tumorigenesis in Glioblastoma: Which Relationship?
Medicina (Kaunas). 2022 Sep 26, 2022;58(10):1349. doi: 10.3390/medicina58101349. PMID: 36295510. Review.

Song S, Wu H, Wang F, Jiao J, Xu L, Wang H, Tong X, Yan H.
Global research trends and hotspots on glioma stem cells.
Front Oncol. 2022 Sep 29, 2022;12:926025. doi: 10.3389/fonc.2022.926025. PMID: 36248966. Bibliometric analysis.

Zhou Y, Fang C, Xu H, Yuan L, Liu Y, Wang X, Zhang A, Shao A, Zhou D.
Ferroptosis in glioma treatment: Current situation, prospects and drug applications.
Front Oncol. 2022 Sep 29, 2022;12:989896. doi: 10.3389/fonc.2022.989896. PMID: 36249003. Review.

Buccarelli M, Castellani G, Ricci-Vitiani L.
Glioblastoma-Specific Strategies of Vascularization: Implications in Anti-Angiogenic Therapy Resistance.
J Pers Med. 2022 Oct 1, 2022;12(10):1625. doi: 10.3390/jpm12101625. PMID: 36294763. Review.

Daneshimehr F, Barabadi Z, Abdolahi S, Soleimani M, Verdi J, Ebrahimi-Barough S, Ai J.
Angiogenesis and Its Targeting in Glioblastoma with Focus on Clinical Approaches.
Cell J. 2022 Oct 1, 2022;24(10):555-568. doi: 10.22074/cellj.2022.8154. PMID: 36259473. Review.

Guha A, Goda JS, Dasgupta A, Mahajan A, Halder S, Gawde J, Talole S.
Classifying primary central nervous system lymphoma from glioblastoma using deep learning and radiomics based machine learning approach - a systematic review and meta-analysis.
Front Oncol. 2022 Oct 3, 2022;12:884173. doi: 10.3389/fonc.2022.884173. PMID: 36263203. Review, Meta-analysis.

Choi SI, Yin J.
Prospective approaches to enhancing CAR T cell therapy for glioblastoma.
Front Immunol. 2022 Oct 6, 2022;13:1008751. doi: 10.3389/fimmu.2022.1008751. PMID: 36275671. Review.

Sánchez-Villalobos JM, Aledo-Serrano Á, Villegas-Martínez I, Shaikh MF, Alcaraz M.
Epilepsy treatment in neuro-oncology: A rationale for drug choice in common clinical scenarios.
Front Pharmacol. 2022 Oct 6, 2022;13:991244. doi: 10.3389/fphar.2022.991244. PMID: 36278161. Review.

Bartusik-Aebisher D, Żołyniak A, Barnaś E, Machorowska-Pieniążek A, Oleś P, Kawczyk-Krupka A, Aebisher D.
The Use of Photodynamic Therapy in the Treatment of Brain Tumors-A Review of the Literature.
Molecules. 2022 Oct 13, 2022;27(20):6847. doi: 10.3390/molecules27206847. PMID: 36296440. Review.

van Bree NFHN, Wilhelm M.
The Tumor Microenvironment of Medulloblastoma: An Intricate Multicellular Network with Therapeutic Potential.
Cancers (Basel). 2022 Oct 13, 2022;14(20):5009. doi: 10.3390/cancers14205009. PMID: 36291792. Review.

Gaca-Tabaszewska M, Bogusiewicz J, Bojko B.
Metabolomic and Lipidomic Profiling of Gliomas-A New Direction in Personalized Therapies.
Cancers (Basel). 2022 Oct 14, 2022;14(20):5041. doi: 10.3390/cancers14205041. PMID: 36291824. Review.

Gueble SE, Vasquez JC, Bindra RS.
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.
Curr Treat Options Oncol. 2022 Oct 15, 2022;23(11):1566-1589. doi: 10.1007/s11864-022-01024-5. PMID: 36242713. Review˰

Knisely JPS, Fine HA.
Reirradiation for Recurrent Glioblastoma: What We Know and What We Do Not.
J Clin Oncol. 2022 Oct 19, 2022:JCO2201785. doi: 10.1200/JCO.22.01785. PMID: 36260825. Case report, Review.

Mackenzie P, Vajdic C, Delaney G, Comans T, Morris L, Agar M, Gabriel G, Barton M.
Radiotherapy utilisation rates for patients with cancer as a function of age: A systematic review.
J Geriatr Oncol. 2022 Oct 19, 2022:S1879-4068(22)00236-3. doi: 10.1016/j.jgo.2022.10.002. PMID: 36272958. Review˰

Niemi JVL, Sokolov AV, Schiöth HB.
Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments.
Cancers (Basel). 2022 Oct 21, 2022;14(20):5163. doi: 10.3390/cancers14205163. PMID: 36291947. Review.

Sachdeva P, Ghosh S, Ghosh S, Han S, Banerjee J, Bhaskar R, Sinha JK.
Childhood Obesity: A Potential Key Factor in the Development of Glioblastoma Multiforme.
Life (Basel). 2022 Oct 21, 2022;12(10):1673. doi: 10.3390/life12101673. PMID: 36295107. Review.

Yuile A, Satgunaseelan L, Wei J, Kastelan M, Back MF, Lee M, Wei H, Buckland ME, Lee A, Wheeler HR.
Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma-A Case Report and Systematic Review.
Curr Issues Mol Biol. 2022 Oct 21, 2022;44(10):5117-5125. doi: 10.3390/cimb44100348. PMID: 36286062. Case report, Review.

Fioni F, Song JC, Ma ZL, Ghalwash AA.
Differentiation of high grade glioma and solitary brain metastases by measuring relative cerebral blood volume and fractional anisotropy: A systematic review and Meta-Analysis of MRI diagnostic test accuracy studies.
Br J Radiol. 2022 Oct 24, 2022:20220052. doi: 10.1259/bjr.20220052. PMID: 36278795. Review, Meta-analysis.

Bunse L, Bunse T, Krämer C, Chih YC, Platten M.
Clinical and Translational Advances in Glioma Immunotherapy.
Neurotherapeutics. 2022 Oct 27. doi: 10.1007/s13311-022-01313-9. PMID: 36303101. Review.

Giambra M, Di Cristofori A, Valtorta S, Manfrellotti R, Bigiogera V, Basso G, Moresco RM, Giussani C, Bentivegna A.
The peritumoral brain zone in glioblastoma: where we are and where we are going.
J Neurosci Res. 2022 Oct 27. doi: 10.1002/jnr.25134. PMID: 36300592. Review.

Hosseinalizadeh H, Habibi Roudkenar M, Mohammadi Roushandeh A, Kuwahara Y, Tomita K, Sato T.
Natural killer cell immunotherapy in glioblastoma.
Discov Oncol. 2022 Oct 28, 2022;13(1):113. doi: 10.1007/s12672-022-00567-1. PMID: 36305981. Review.

Qi X, Jha SK, Jha NK, Dewanjee S, Dey A, Deka R, Pritam P, Ramgopal K, Liu W, Hou K.
Antioxidants in brain tumors: current therapeutic significance and future prospects.
Mol Cancer. 2022 Oct 28, 2022;21(1):204. doi: 10.1186/s12943-022-01668-9. PMID: 36307808. Review.